A Beta-Blocker That Spares the Resting Heart
Acebutolol is a cardioselective beta-blocker with a distinctive pharmacological feature: intrinsic sympathomimetic activity (ISA). In other words, while blocking the receptor, it also exerts a slight partial stimulation on it.
This property softens the slowing of the heart rate at rest and can be useful for certain patients. It is used in hypertension, rhythm disorders, and angina pectoris.
Origin and Discovery
Like all beta-blockers, acebutolol is a synthetic molecule that builds on the pioneering work of James Black. It was developed by the French laboratories Rhône-Poulenc (via May & Baker) and marketed from the 1970s onward under the name Sectral®.
It belongs to the generation of beta-blockers with ISA, designed to better respect the baseline heart rate.
Chemical Structure and Synthesis
Acebutolol shares the aryloxypropanolamine backbone common to beta-blockers, carried by a substituted aromatic ring (with an acetyl group and an amide function). It is produced by chemical synthesis and then salified as a hydrochloride.
In the body, it is converted into an active metabolite, diacetolol, which extends and sustains its action.
Pharmacological Properties and Mechanism of Action
Acebutolol combines three properties: preferential blockade of cardiac β1 receptors; intrinsic sympathomimetic activity (partial agonism), which limits resting bradycardia; and a mild membrane-stabilizing effect.
The result is a reduction in heart rate and contractility during exertion, a drop in blood pressure, and an antiarrhythmic action, with a smaller impact on the heart at rest than 'pure' beta-blockers.
Therapeutic Use and Precautions
The main indications are arterial hypertension, cardiac rhythm disorders (certain supraventricular and ventricular arrhythmias), and angina pectoris.
Precautions: as with any beta-blocker, discontinuation must be gradual, and the drug should be used with caution in cases of asthma, marked bradycardia, or conduction disorders.